AIxCrypto Holdings, Inc.
AIXCNASDAQTechnologySoftware - Infrastructure
Previous close
$1.12
−$0.055 · -4.68%
AIXC company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
44
Fair Value
Momentum
17
Strong Down
Sentiment
55
Mixed
Risk resilience
30
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteAIxCrypto Holdings, Inc. is a clinical-stage biopharmaceutical company committed to discovering and developing innovative treatments for both adult and pediatric oncology. Its leading investigational therapeutic, QN-302, is a small molecule G-quadruplexes (G4)-selective transcription inhibitor currently progressing through Phase I clinical trials for pancreatic cancer and a range of other solid tumors. The firm is also advancing Pan-RAS, a preclinical-stage program targeting advanced solid tumors. Founded in 1996 and headquartered in Carlsbad, California, the company rebranded from Qualigen Therapeutics, Inc. to AIxCrypto Holdings, Inc. in November 2025.
- Industry
- Software - Infrastructure
- Sector
- Technology
- Headquarters
- US
- CEO
- Jiawei Wang
- Listed since
- Jun 23, 2015
- Employees
- 10
Market position
Day range
Current $1.12
52-week range
Current $1.12
- Open
- $1.24
- Previous close
- $1.175
- Volume
- 492.51K
- 0.57× average
- Average volume
- 858.03K
- Average daily volume
- Market cap
- 22.66M USD
- Beta
- 0.53
- Market reference 1
- 50-day average
- $0.9962
- +12.42% above average
- 200-day average
- $1.5868
- -29.42% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- -13.56M USD
- EV / EBITDA
- 0.85×
- Earnings yield
- -301.12%
- Free cash flow yield
- -417.89%
Profitability & efficiency
- Return on equity
- -60.70%
- Return on assets
- -54.24%
- Return on invested capital
- -46.99%
Financial health
- Current ratio
- 9.3×
- Altman Z-score
- -29.07
- Piotroski F-score
- 2 of 9
Earnings
- EPS beat rate
- 86%
- 6 beats, 1 miss, 0 met estimates
- Average EPS surprise
- +47.16%
- 7 comparable reports
- Latest EPS result
- -0.21
- Estimate -70 · Beat by 99.70%
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
AIXC peers
ETFs holding AIXC
Funds reporting this stock among their holdings, ordered by reported position size.
Continue in GoAI
Research AIXCresearch.disclaimer